StoxGlobal Health vs Acutaas Chemicals: share price & financials comparison
NSE: MEDANTA vs ACUTAAS · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Global Health vs Acutaas Chemicals at a glance
Global Health (MEDANTA) has a market capitalisation of ₹39,065 Cr, against ₹33,069 Cr for Acutaas Chemicals (ACUTAAS). Over the past year Acutaas Chemicals has returned +120.2%, compared with +16.4% for Global Health. On valuation, Acutaas Chemicals trades at a lower P/E of 75.3 versus 98.2. Acutaas Chemicals earns a higher return on equity (23.6% vs 9.2%). Global Health comes out ahead on size. Acutaas Chemicals comes out ahead on valuation, profitability, growth, financial health, momentum and technicals. Across the scored metrics below, Global Health leads on 2 and Acutaas Chemicals on 14. On StoxGud's 10-point checklist, Global Health scores 6/10 and Acutaas Chemicals scores 8/10.
| Metric | Global Health | Acutaas Chemicals |
|---|---|---|
| Size | ||
| Market cap | ₹39,065 Cr | ₹33,069 Cr |
| Revenue (latest FY) | ₹4,410 Cr | ₹1,339 Cr |
| Net profit (latest FY) | ₹556 Cr | ₹356 Cr |
| Valuation | ||
| P/E | 98.2 | 75.3 |
| P/B | 9.04 | 17.80 |
| Dividend yield | 0.03% | 0.04% |
| Profitability | ||
| Return on equity | 9.2% | 23.6% |
| Net profit margin | 7.9% | 27.6% |
| Operating margin | 22.1% | 39.1% |
| Growth | ||
| Revenue growth (YoY) | +33.6% | +42.7% |
| Net profit growth (YoY) | -100.0% | +73.3% |
| Revenue CAGR (multi-year) | +17.9% | +26.7% |
| Financial health | ||
| Debt to equity | 0.16 | 0.00 |
| Momentum | ||
| 1-month return | +13.6% | +27.1% |
| 1-year return | +16.4% | +120.2% |
| 3-year CAGR | +16.9% | +95.5% |
| 5-year CAGR | — | +52.3% |
| Distance from 52W high | -3.6% | +0.0% |
| Technicals | ||
| RSI (14) | 88 | 79 |
| Price vs 200-day avg | +15.9% | +38.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Global Health | Acutaas Chemicals |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Global Health or Acutaas Chemicals?
Global Health has a market cap of ₹39,065 Cr and Acutaas Chemicals has a market cap of ₹33,069 Cr as of 13 Nov 2026.
Which has a lower P/E, Global Health or Acutaas Chemicals?
Acutaas Chemicals has the lower P/E: Global Health trades at 98.2 and Acutaas Chemicals at 75.3.
Which gave better returns in the last year, Global Health or Acutaas Chemicals?
Acutaas Chemicals did better: Global Health returned +16.4% and Acutaas Chemicals returned +120.2% over one year.
What is the difference between Global Health and Acutaas Chemicals?
Both are NSE-listed companies in Healthcare. Global Health is about 1.2 times the size of Acutaas Chemicals by market cap. In the latest financial year Global Health reported revenue of ₹4,410 Cr and Acutaas Chemicals ₹1,339 Cr. Operating margin is 22.1% for Global Health and 39.1% for Acutaas Chemicals. Debt to equity is 0.16 for Global Health and 0.00 for Acutaas Chemicals.
Which is better, Global Health or Acutaas Chemicals?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Global Health leads on 2 and Acutaas Chemicals on 14. Global Health is ahead on size. Acutaas Chemicals is ahead on valuation, profitability, growth, financial health, momentum and technicals. On StoxGud's rules-based checklist Global Health scores 6/10 and Acutaas Chemicals scores 8/10. This is information, not advice: consult a SEBI-registered adviser before investing.